亨迪药业：宁康企管、倍康企管、雷小艳拟分别减持1%、0.33%、1%

Group 1 - The company Hendi Pharmaceutical announced that shareholder Ningkang Enterprise Management holds 23.49 million shares, accounting for 5.63%, and plans to reduce its holdings by up to 4.176 million shares, representing 1%, through block trading or centralized bidding from December 4, 2025, to March 3, 2026 [1] - Shareholder Beikang Enterprise Management, holding 7.83 million shares, which is 1.88%, intends to reduce its stake by up to 1.392 million shares, equivalent to 0.33%, during the same period [1] - Shareholder Lei Xiaoyan, with 15.66 million shares, accounting for 3.75%, plans to reduce holdings by up to 4.176 million shares, representing 1%, from November 18, 2025, to February 17, 2026 [1]